KMKeiji Miyazawa

Keiji Miyazawa

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Keiji Miyazawa has a total of 32 co-authors. Here are the top co-authors by number of shared publications:

  • Kohei Miyazono

    The §Department of Molecular Pathology, Graduate School of Medicine, University of Tokyo, Tokyo 113-0033, Japan

    5 shared publications
  • Masao Saitoh

    Department of Biochemistry, Interdisciplinary Graduate School of Medicine, University of Yamanashi, Yamanashi 409-3898, Japan

    4 shared publications
  • Kazunobu Isogaya

    The §Department of Molecular Pathology, Graduate School of Medicine, University of Tokyo, Tokyo 113-0033, Japan

    2 shared publications
  • Keiko Yuki

    Department of Molecular Pathology, Graduate School of Medicine, University of Tokyo, Tokyo 113-0033; Kasai R & D Center, Daiichi Sankyo Co. Ltd, Tokyo 134-8630; Department of Applied Biological Chemistry, Graduate School of Agricultural and Life Sciences, University of Tokyo, Tokyo 113-0032; and Department of Biochemistry, Interdisciplinary Graduate School of Medicine and Engineering, University of Yamanashi, Chuo, Yamanashi 409-3898, Japan

    2 shared publications
  • Mitsuyoshi Motizuki

    Department of Biochemistry, Interdisciplinary Graduate School of Medicine, University of Yamanashi, Yamanashi 409-3898, Japan

    2 shared publications
  • Yuto Kamiya

    Department of Molecular Pathology, Graduate School of Medicine, University of Tokyo, Bunkyo-ku, Tokyo 113-0033, Japan

    2 shared publications

Latest Publications

  • Maid is a negative regulator of transforming growth factor-β-induced cell migration

    by Mitsuyoshi Motizuki, Masao Saitoh, Keiji Miyazawa

    Maternal Id-like molecule (Maid) is a dominant negative helix-loop-helix protein that has been implicated in regulating gene expression as well as cell-cycle progression. Overexpressed Maid was previously shown to inhibit certain cellular responses induced by transforming growth factor-β (TGF-β), such as TGF-β-induced cytostasis and cell motility, but not epithelial–mesenchymal transition (EMT). The role of endogenous Maid in regulating TGF-β signalling, however, has not been elucidated. We have found evidence that endogenous Maid negatively regulates TGF-β-induced cell motility. Maid knockdown enhanced TGF-β-induced cell motility as measured by chamber migration and wound healing assays but did not affect cell motility induced by bone morphogenetic protein (BMP)-4. Endogenous Maid does not appear to be involved in regulating TGF-β-induced cytostasis, resistance to apoptosis or EMT. Notably, Maid expression was induced in the delayed phase (later than 24 h) after TGF-β stimulation whereas the expression of two other negative feedback regulators, Smad7 and SnoN, was induced as early as 1 h after stimulation. These findings indicate that Maid is a unique negative feedback regulator of TGF-β signalling in its mode of action as well as the timing of its induction.


  • Open Access

    Oligodendrocyte Transcription Factor 1 (Olig1) Is a Smad Cofactor Involved in Cell Motility Induced by Transforming Growth Factor-β

    by Mitsuyoshi Motizuki, Kazunobu Isogaya, Kunio Miyake, Hiroaki Ikushima, Takeo Kubota, Kohei Miyazono, Masao Saitoh, Keiji Miyazawa


  • Open Access

    A negative regulator or just an unconcerned passerby: phosphoinositide 3-kinase signalling in IL-12 production

    by Keiji Miyazawa

    Pathogens are eliminated from the host by the cooperative functions of the innate and adaptive immune systems, where interleukin 12 (IL-12) plays a crucial role. As overactivity of IL-12 can lead to autoimmune-mediated tissue damage, IL-12 production is tightly regulated. Notably, the phosphoinositide 3-kinase (PI3K) pathway suppresses Toll-like receptor (TLR)-induced IL-12 production as an auto-inhibitory regulator in dendritic cells. However, Okazaki et al. (C5a controls TLR-induced IL-10 and IL-12 production independent of phosphoinositide 3-kinase. J. Biochem. 2011;149:265–274) recently indicated that PI3K activated downstream of C5a anaphylatoxin does not affect the induction of IL-12 by TLR, although C5a efficiently inhibits the induction, in macrophages. PI3K is thus a context-dependent regulator of TLR-mediated IL-12 production.


  • Open Access

    Phosphoinositide 5-phosphatases: how do they affect tumourigenesis?

    by Keiji Miyazawa

    The activity of biological molecules is often affected by their phosphorylation state. Regulatory phosphorylation operates as a binary switch and is usually controlled by counteracting kinases and phosphatases. However, phosphatidylinositol (PtdIns) has three phosphorylation sites on its inositol ring. The phosphorylation status of PtdIns is controlled by multiple kinases and phosphatases with distinct substrate specificities, serving as a ‘lipid code’ or ‘phosphoinositide code’. Class I phosphoinositide 3-kinase (PI3K) converts PtdIns(4,5)P2 to PtdIns(3,4,5)P3, which plays a pivotal role in signals controlling glucose uptake, cytoskeletal reorganization, cell proliferation and apoptosis. PI3K is pro-oncogenic, whereas phosphoinositide phosphatases that degrade PtdIns(3,4,5)P3 are not always anti-oncogenic. Recent studies have revealed the unique characteristics of phosphoinositide 5-phosphatases.


  • Open Access

    Phosphorylation in the activation loop as the finishing touch in c-Kit activation

    by Keiji Miyazawa

    Receptor tyrosine kinases are a group of transmembrane proteins that transmit signals in response to stimulation by ligands including growth factors and cytokines. They share a common mechanism of activation through receptor dimerization or oligomerization, but subsequent routes to their full activation appear to be various. A recent paper published by DiNitto et al. (Function of activation loop tyrosine phosphorylation in the mechanism of c-Kit autoactivation and its implication in sunitinib resistance. J. Biochem. 2010;147:601–609) analysed a process of c-Kit autoactivation in detail. They revealed that phosphorylation in the activation loop, which is crucial for activation of many types of tyrosine kinases, is dispensable for c-Kit activation. However, the phosphorylation affects the sensitivity of c-Kit to kinase inhibitors, thus representing the finishing touch in c-Kit activation.


  • Open Access

    Encountering unpredicted off-target effects of pharmacological inhibitors

    by Keiji Miyazawa

    With the emergence of chemical biology, the use of pharmacological inhibitors in biological research has been expanding. SP600125 is a low-molecular weight compound that has been widely used to inhibit c-Jun-N-terminal kinase (JNK). A recent publication by Tanemura et al. (J. Biochem. 145:345–354, 2009) indicated that SP600125 also inhibits phosphatidylinositol 3-kinase (PI3K) in an isoform-selective fashion: it efficiently inhibited the delta isoform of p110 catalytic subunit (p110δ), which is primarily expressed in leucocytes, but neither of the ubiquitously expressed isoforms, p110α and p110γ. Here, I discuss what we learn from such unpredicted off-target effects of pharmacological inhibitors.


  • Identification of a phosphorylation site in c-Ski as serine 515

    by Motoko Nagata, Shinji Nagata, Keiko Yuki, Kazunobu Isogaya, Masao Saitoh, Kohei Miyazono, Keiji Miyazawa

    C-Ski has been known to be phosphorylated at serine residue(s), which results in slower migration of c-Ski in SDS–polyacrylamide gel electrophoresis. The position(s) of phosphorylation, however, has not been determined. In the present study, we identified a phosphorylation site of c-Ski which affects its electrophoretic motility as serine 515 using MALDI–TOF mass spectrometry. A phosphorylation-resistant mutant, c-Ski S515A, did not exhibit a phosphatase-sensitive band shift. In addition, we confirmed that endogenous c-Ski is phosphorylated at serine 515, using a specific antibody. The phosphorylation status of c-Ski, however, does not appear to affect its stability or effects on TGF-β signalling. Identification of the phosphorylation site of c-Ski would allow us further examination of physiological significance of c-Ski phosphorylation.


  • Hepatocyte growth factor activator (HGFA): a serine protease that links tissue injury to activation of hepatocyte growth factor

    by Keiji Miyazawa

    Growth factors are a group of proteins that regulate a wide variety of cellular processes, including proliferation, differentiation, motility, adhesion, and apoptosis of target cells. They play crucial roles in the formation and maintenance of tissue architecture in embryonic development and adult tissue homeostasis. Because aberrations in growth factor signaling often result in pathological conditions, the activities of growth factors are tightly controlled by extracellular and intracellular regulators. Hepatocyte growth factor (HGF) is a mesenchymal cell‐derived growth factor that affects various target cells, including epithelial and endothelial cells. HGF is synthesized and secreted as a latent form, and is proteolytically activated in response to tissue injury, thus participating in tissue regeneration and repair. Interestingly, HGF has a unique structural feature: it is homologous to plasminogen, a key enzyme in the fibrinolytic system. Elucidation of the regulatory mechanisms of HGF activity has revealed that a blood coagulation factor XII‐like serine protease, hepatocyte growth factor activator, efficiently converts HGF from the latent form to the active form. Hepatocyte growth factor activator itself is activated downstream of the blood coagulation cascade, and links tissue injury to activation of HGF. HGF thus has structural as well as functional relevance to the blood coagulation/fibrinolytic system.


  • SUMO amplifies TGF-β signalling

    by Kohei Miyazono, Yuto Kamiya, Keiji Miyazawa

    Transforming growth factor-β (TGF-β) stimulates phosphorylation of TGF-β type I receptor. This receptor is now shown to be sumoylated, leading to enhanced activation and modulation of the downstream Smad signalling pathway.